Literature DB >> 19802609

[Diagnostic of prostate cancer: conventional and molecular or cell biological methods].

M Susani1, L Kenner, Z Culig.   

Abstract

At present the diagnosis of prostate cancer is carried out by transrectally obtained biopsy samples. The histological findings, the value for prostate-specific antigen (PSA) in the serum, and the clinical stage are the objective criteria for all subsequent therapy decisions. In over 95% of cases an acinar "usual" form of prostate cancer is diagnosed but can be very different in characteristics and differentiation. In order to correctly assess prostate cancer and to be able to select the best possible therapeutic measures resulting from the diagnosis, all information obtained from the biopsy must be used to a maximum. The demands on the optimal biopsy findings have considerably expanded in recent years. It must be able to obtain all additional biological, molecular and genetic findings from the biopsy material.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802609     DOI: 10.1007/s00292-009-1213-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  20 in total

Review 1.  Current practice of Gleason grading of prostate carcinoma.

Authors:  Antonio Lopez-Beltran; Gregor Mikuz; Rafael J Luque; Roberta Mazzucchelli; Rodolfo Montironi
Journal:  Virchows Arch       Date:  2005-11-23       Impact factor: 4.064

Review 2.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

3.  Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled.

Authors:  Mehsati Herawi; Hillel Kahane; Christina Cavallo; Jonathan I Epstein
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

4.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

5.  PSA testing in Austria: induced morbidity and saved mortality.

Authors:  Christian Vutuc; Thomas Waldhoer; Gerhard Lunglmayr; Wolfgang Hoeltl; Gerald Haidinger
Journal:  Eur J Cancer Prev       Date:  2009-09       Impact factor: 2.497

Review 6.  The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers.

Authors:  Ming Zhou; Jonathan I Epstein
Journal:  Pathology       Date:  2003-12       Impact factor: 5.306

7.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

8.  TMPRSS2-ERG and PTEN loss in prostate cancer.

Authors:  Jeremy A Squire
Journal:  Nat Genet       Date:  2009-05       Impact factor: 38.330

9.  Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?

Authors:  Mark A Rubin; Tarek A Bismar; Sarah Curtis; James E Montie
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

10.  Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Authors:  Hannes Neuwirt; Martin Puhr; Frédéric R Santer; Martin Susani; Wolfgang Doppler; Gemma Marcias; Veronika Rauch; Maria Brugger; Alfred Hobisch; Lukas Kenner; Zoran Culig
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.